For the past century, most of the methods utilized by physicians to determine when a skin biopsy is necessary have depended on observations made by the naked eye. Until recently, whenever a mole or spot was categorized as suspicious, a surgical biopsy was required to rule out skin cancer. Although this has traditionally been the standard accepted protocol for skin cancer detection and prevention,
the vast majority of skin biopsies of moles in the United States result in a benign diagnosis, which means that the surgery – and any discomfort or scarring associated with it – were unnecessary. With the VivaCam™ Dermoscopy system we can monitor your skin for new or changing moles, and if a suspicious mole or lesion is found, we can examine the cells in the lesion completely non-invasively with VivaScan™ Confocal Microscopy. Combining these two techniques, only a small percentage of moles may ultimately need to be surgically removed. At NIDIskin, we systematically rule out benign moles as candidates for biopsy using a 3-step process:
-Map and notate all moles using VivaCam™ Total Body Imaging
-Capture magnified and illuminated images of any moles that require monitoring with VivaCam™ Dermatoscopy
-Examine cellular structure of any high-risk moles with VivaScan™ Confocal Microscopy
and because our technology is completely non-invasive, we can test the same spot repeatedly over time without any discomfort or leaving any traces on the skin. Non-Invasive Diagnostic Imaging of the Skin also allows us the freedom to monitor and investigate more moles that might otherwise have gone unchecked. Now, we can accurately and responsibly manage skin lesions over time, and be certain when surgery is necessary.
